




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|--|---|---|
| (51) International Patent Classification 5 : C12Q 1/68, 1/70 | | A1 | (11) International Publication Number: WO 93/10263 (43) International Publication Date: 27 May 1993 (27.05.93) |
| <p>(21) International Application Number: PCT/US92/09604</p> <p>(22) International Filing Date: 12 November 1992 (12.11.92)</p> <p>(30) Priority data: 07/792,585 15 November 1991 (15.11.91) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 07/792,585 (CIP) Filed on 15 November 1991 (15.11.91)</p> <p>(71) Applicant (for all designated States except US): DIGENE DIAGNOSTICS, INC. [US/US]; 2301-B Broadbirch Drive, Silver Spring, MD 20904 (US).</p> | | <p>(72) Inventors; and (75) Inventors/Applicants (for US only) : CHALLBERG, Sharon [US/US]; 12400 West Old Baltimore Road, Boyds, MD 20841 (US). LORINCZ, Attila [IE/US]; 19409 Poinsetta Court, Gaithersburg, MD 20879 (US). LAZAR, James, G. [US/US]; 5301 Westbard Circle, Bethesda, MD 20816 (US). CULLEN, Allison [US/US]; 1200 Ed-Glenn Drive, Woodbine, MD 21797 (US). IMPRAIM, Chaka [GH/US]; 448 Coventry Place, Danville, CA 94506 (US).</p> <p>(74) Agents: PABST, Patrea, L. et al.; Kilpatrick & Cody, 1100 Peachtree Street, Suite 2800, Atlanta, GA 30309-4530 (US).</p> <p>(81) Designated States: AU, FI, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> | |

(54) Title: NON-RADIOACTIVE HYBRIDIZATION ASSAY AND KIT



(57) Abstract

A non-radioactive hybridization assay and kit for the detection of genetic defects, microbial infections or viral infections, such as human papillomavirus. A test sample is treated with a base and incubated with nucleic acid probes, diluted in a neutralizing buffer, specific for target nucleic acids. The hybrids are captured onto a solid phase coated with an anti-hybrid antibody, unhybridized probe is eliminated, and the bound hybrid detected.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AT | Austria | FR | France | MR | Mauritania |
| AU | Australia | GA | Gabon | MW | Malawi |
| BB | Barbados | GB | United Kingdom | NL | Netherlands |
| BE | Belgium | GN | Guinea | NO | Norway |
| BF | Burkina Faso | GR | Greece | NZ | New Zealand |
| BC | Bulgaria | HU | Hungary | PL | Poland |
| RJ | Benin | IE | Ireland | PT | Portugal |
| BR | Brazil | IT | Italy | RO | Romania |
| CA | Canada | JP | Japan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SK | Slovak Republic |
| CI | Côte d'Ivoire | LJ | Liechtenstein | SN | Senegal |
| CM | Cameroon | LK | Sri Lanka | SU | Soviet Union |
| CS | Czechoslovakia | LU | Luxembourg | TD | Chad |
| CZ | Czech Republic | MC | Monaco | TG | Togo |
| DE | Germany | MC | Madagascar | UA | Ukraine |
| DK | Denmark | ML | Mali | US | United States of America |
| ES | Spain | MN | Mongolia | VN | Viet Nam |
| FI | Finland | | | | |

NON-RADIOACTIVE HYBRIDIZATION ASSAY AND KIT

This relates to the field of hybridization probe assays in general and more particularly relates to a non-radioactive hybridization immunoassay.

Background of the Invention**5 Hybridization Probes**

The RNA or DNA for many microorganisms and viruses have been isolated and sequenced. Nucleic acid probes are currently available to identify a large number of infections. Nucleic acid probes 10 are detectable nucleic acid sequences that hybridize to complementary RNA or DNA sequences in a test sample. Detection of the probe indicates the presence of a particular nucleic acid sequence in the test sample for which the probe is specific. 15 In addition to aiding scientific research, DNA or RNA probes can be used to detect the presence of viruses and microorganisms such as bacteria, yeast and protozoa as well as genetic mutations linked to specific disorders in patient samples. Grunstein 20 et al., *Proc. Natl. Acad. Sci. USA* 72:3961 (1975) and Southern, *J. Mol. Biol.* 98:503 (1975) describe hybridization techniques using radiolabelled nucleic acid probes. Nucleic acid hybridization probes have the advantages of high sensitivity and 25 specificity over other detection methods and do not require a viable organism. Hybridization probes are often labelled with a radioactive substance that can be easily detected. A radioactive hybridization assay for HPV is currently available 30 in the form of the ViraTypeTM or ViraPapTM kit by Digene Diagnostics (Silver Spring, MD).

The existing hybridization techniques that utilize radioisotopes to label probes introduce additional expenses for disposal of radioactive

waste products and monitoring of personnel and the workplace for contamination. In addition, the short half-life of radioactive compounds such as ^{32}P requires that radioactive probes be produced 5 frequently. Radioactive nucleic acid hybridization is therefore discouraged in commercial areas such as clinical diagnosis.

10 Probes have been indirectly labelled in an attempt to avoid the problems associated with direct radioactive labelling. The most common method of indirect labelling is to attach biotin, a small vitamin, to the nucleic acid using a chemical or enzymatic technique. Following hybridization, the biotin is detected by reaction with avidin, an 15 egg white protein which has been labelled with an enzyme or fluorochrome. Bound enzyme can be detected by reaction with color-producing substrates and the fluorochrome can be seen when reacted with incident light of appropriate 20 wavelength. Indirect labelling of hybridization probes with biotin or other haptens often increases the "hydrophobicity" of the probe. The probe tends to interact non-specifically with materials other than the complementary nucleic acid target, leading 25 to high background. High background reduces sensitivity and increases the likelihood of a false-positive result. Indirect labelling is also less sensitive than direct labelling because the labelling density is limited; only a small fraction 30 of the bases are labelled giving a limiting number of sites for signal generation. An increase in the labelling density of a probe leads to increased non-specific binding, higher background, and ultimately, failure of the probe to hybridize with 35 its target due to the interference of the hapten with base pairing. Indirectly labelled probes are therefore not well suited to clinical diagnosis.

Hybridization has been detected with the use of an intercalating agent such as acridine orange or ethidium bromide as described in U.S. Patent No. 4,563,417 to Albarella et al. The intercalating agent becomes inserted between hybridized base pairs of probe and sample nucleic acids and causes the tertiary structure of the helix to unwind. An antibody specific for the newly formed antigenic determinant created by the intercalating agent and the unwound helix is detected by conventional means. This method lacks selectivity for the target hybrids because intercalating agents fail to recognize specific sequences. Furthermore, the antibodies recognize only the intercalating agent/nucleic acid complex, but do not detect a specific sequence. Therefore, additional selection or purification steps are required to prevent non-specific signal, making this approach poorly suited for clinical diagnosis.

Hybridization can also be detected with the aid of an antibody specific for a labelled probe as described in U.S. Patent No. 4,743,535 to Carrico. The probe is labelled with a detectable substance such as flavin adenine dinucleotide (FAD) or a fluorescent agent. An antibody specific for the labelled probe, after it has hybridized to the sample nucleic acid, is detected by a biochemical reaction. This method of detection also creates non-specific binding and the likelihood of false-positive results and is not well suited for clinical screening.

Monoclonal antibodies to DNA-RNA hybrids are now available. U.S. Patent No. 4,732,847 to Stuart et al. and the publication of Stuart et al., *Proc. Natl. Acad. Sci., USA* 78:3751 (1981) describe a method of hybridization detection involving a monoclonal antibody specific for a poly(A)-poly(dT)

duplex. A monoclonal antibody specific for DNA-RNA hybrids, secreted by hybridoma HB 8730, is disclosed in U.S. Patent No. 4,833,084 to Carrico et al. The isolation of anti-DNA-RNA hybridomas 5 has improved the development of assays for genetic mutations linked to specific defects and the detection of bacterial and viral infections. However, assays utilizing these anti-hybrid monoclonal antibodies often suffer from a high 10 level of non-specific binding causing false positive results. Boguslawski et al., *J. Immunol. Methods* 89:123-130 (1986) developed a hybridization assay using anti-hybrid coated polystyrene beads isolated on filter paper in an attempt to reduce 15 non-specific binding and avoid complicated washing procedures.

Methods of amplifying nucleic acid sequences are commercially available. These methods include the polymerase chain reaction (PCR), the ligation 20 amplification reaction (LCR), and the transcription based amplification reaction. PCR technology is described in *PCR Protocols A Guide to Methods and Applications* by Michael A. Innis, David H. Gelfand, John J. Sninsky and Thomas J. White, pp. 39-45 and 25 337-385 (Academic Press, Inc., Harcourt Brace Jovanovich, Publishers, 1990). PCR technology is also described by Marx, J.L., *Science* 140:1408-1410 (1988) and in U.S. Patent Nos. 4,683,195 and 4,683,202, to Mullis. Ligation amplification 30 reaction is described by Wu, D.Y and Wallace, R.B., *Genomics* 4:560-569 (1989) and Barringer, K.J., et al., *Gene* 89:117-122 (1990). Transcription based amplification reaction is described by Kwoh, D.Y., et al., *Proc. Natl. Acad. Sci. USA* 86:1173-1177 35 (1989). These methods have the advantages of high sensitivity, but the disadvantages of being prone to false-positive results from reaction product

contamination. Amplification reaction products must be detected by a hybridization assay.

Infections by microorganisms and viruses

Neoplastic transformation of a normal cell to a cancer cell is known to be caused by chemical, physical and viral agents. Several varieties of oncogenic DNA and RNA viruses including papillomavirus and herpes viruses, such as Epstein-Barr virus, are known to induce tumor formation in humans. Prevention of these cancers, such as cervical cancer, lies in early detection and treatment of pre-cancerous disease.

Human papillomavirus, or HPV, has been recognized as the cause of various epithelial lesions such as warts, condylomas and dysplasias as described by Gissmann, L., *Cancer Surv.*, 3:161 (1984); Pfister, H., *Biochem. Pharmacol.*, 99:111 (1983); Durst, M. et al., *Proc. Natl. Acad. Sci., USA*, 80:3812 (1983) and Boshart, M. et al., *EMBO J.*, 3:1151 (1984). Dysplasias of the cervix are believed to be early events in the progression to cervical cancer; the progression proceeding from mild dysplasia (cervical intraepithelial neoplasia I or CIN I) to moderate dysplasia (CIN II) to severe dysplasia, to carcinoma *in situ* (collectively referred to as CIN III) to invasive cancer. Early detection and characterization of HPV is important for preventing progression of the disease to carcinoma.

Numerous types of HPV have been identified, and not all HPV infections are oncogenic. For example, HPV 6 and HPV 11 are associated with benign lesions, whereas HPV 16 and HPV 18 are detected in cervical and other anogenital cancers and their precursor lesions. The determination of the type of HPV infection is therefore essential for proper

diagnosis, risk assessment of cancer development, and treatment.

5 Hepatitis B virus (HBV), formerly termed serum hepatitis, is an occupational disease of health personnel. HBV infection in humans can cause severe jaundice, liver degeneration and death. HBV enters predominantly by the parenteral route, has a characteristic incubation period of 60 to 160 days, and may persist in the blood for years in chronic 10 carriers. HBV is detected by immunologic techniques such as immune electron microscopy, complement-fixation, immune adherence, enzyme-linked immunosorbent assay (ELISA) or radioimmunoassay (RIA). All blood for transfusion 15 must be screened for HBV to prevent transmission of the virus to blood recipients. Early detection of HBV in infected patients is also important because exposure to blood or objects potentially contaminated with blood or even body excretions may 20 cause infection.

25 Conventional HBV DNA assays test for the presence of hepatitis B virus genomic DNA in human serum using a full genomic (3.2 Kb) RNA probe. For HBV DNA testing a quantitative assay would be particularly advantageous because the level of HBV DNA in serum correlates with severity of liver disease. A quantitative HBV DNA test would be useful for monitoring chronic carriers of HBV undergoing antiviral therapy as detailed by 30 Hoofnagle et al., *J. Hepatol.* 11:S100 (1990).

35 *Chlamydiaceae* (*Chlamydia*) is a family of obligate intracellular bacterial parasites. The organisms are spherical and form intracytoplasmic microcolonies up to 12 microns in diameter. *Chlamydia* infect a number of different birds and mammals including humans. Human diseases caused by *Chlamydia* include trachoma, inclusion

conjunctivitis, various urogenital tract infections, infantile pneumonia, lymphogranuloma venereum, and psittacosis. Two species are recognized, *C. psittaci* and *C. trachomatis*, the latter being inhibited by sulfonamides. Most of the human *Chlamydia* infections are caused by various strains of *C. trachomatis*. *C. psittaci* is found mainly in birds and mammals, but can cause some disease in humans.

10 Diagnosis of *Chlamydia* is accomplished by either the complement-fixation test or the microimmunofluorescence technique. Neither test can be used to detect all human chlamydial infections. The complement-fixation test measures antibody to the antigen lipopolysaccharide (LPS). It is of little use in diagnosing trachoma and genital infections. Many patients without a chlamydial infection are seropositive by the complement fixation test, reducing the sensitivity of this test. The microimmunofluorescence test detects the presence of specific antibodies to strains of *C. trachomatis*. The level of seropositivity for uninfected patients is also high, reducing the sensitivity of this test as well. Direct culture methods have also been used to detect chlamydial infections but these methods require the presence of viable organisms. Enzyme immunoassays have also been used to detect chlamydia-specific antigens, but the performance of these assays is inferior to the above-mentioned culture methods.

In summary, there is a need for a hybridization assay for clinical diagnosis and quantitative analysis of microbial and viral infections, especially HPV, HBV and *Chlamydia*, and genetic mutational defects, that is economically feasible

for screening large numbers of samples with great sensitivity and minimal non-specific binding.

It is therefore an object of the present invention to provide a cost-effective, sensitive, 5 non-radioactive hybridization assay for the detection of nucleic acids in a sample.

It is a further object of the present invention to provide a cost-effective, sensitive, non- radioactive hybridization assay for the 10 quantitation of nucleic acids in a sample.

It is a further object of the present invention to provide a hybridization assay in which sample preparation is simple and rapid.

It is a further object of the present invention 15 to provide a hybridization assay in which sample preparation does not involve extractions, precipitations, centrifugations or other time-consuming purification methods.

It is a further object of the present invention 20 to provide a non-radioactive hybridization assay having minimal false positives.

It is a further object of the present invention to provide an accurately quantitative test for monitoring the level of microbial and viral 25 infection.

It is a further object of the present invention to provide a kit that can be used to screen large numbers of samples for microbial and viral infections.

30 It is a further object of the present invention to provide a method of detecting reaction products from amplification reactions.

Summary of the Invention

Non-radioactive hybridization assays and kits 35 are provided for screening samples for viral and

other specific nucleic acid sequences including amplified nucleic acid sequences. A hybridization buffer is also provided.

A test sample is collected with a chemically inert device and is treated with a base. The treated sample is incubated with nucleic acid probes, diluted in a neutralizing buffer, that are specific for target nucleic acid sequence, such as oncogenic and non-oncogenic HPV DNA sequences, HBV DNA sequences or Chlamydia DNA sequences, for a sufficient amount of time to allow hybridization of the sample nucleic acid sequence to the probes. The hybrids are then bound to anti-hybrid antibodies immobilized on a solid phase. Non-hybridized probe is removed, preferably by incubating the captured hybrids with an enzyme, such as RNAase, that degrades non-hybridized probe. Hybridization is detected by conventional means such as a direct labelled anti-hybrid antibody, a labelled antibody specific for an unlabelled anti-hybrid antibody, a direct labelled probe or a modified probe for which a labelled antibody is specific.

For detection of amplification reaction products, the sample is collected as described above and nucleic acid sequences are amplified by a nucleic acid sequence amplification method, such as the polymerase chain reaction (PCR), using a ligand-bound primer, such as a biotinylated primer. The amplification product is denatured with base and hybridized to unlabelled RNA probe in neutralizing buffer as described above. The hybrids are bound to a solid phase that has been coated with a ligand that is complementary to the ligand bound to the primer, such as avidin, and are detected by conventional means as described above.

Brief Description of the Drawing

Figure 1 is a schematic representation of a first preferred embodiment of the hybridization assay of the present invention for detection of HPV DNA.

5 Figure 2 is a logarithmic dose-response analysis of HBV DNA in human serum detected by the hybridization assay of the present invention showing a linear relationship between relative 10 light units (RLU) and picograms of HBV DNA.

15 Figure 3 is a graph showing detection of polymerase chain reaction (PCR) products by a first preferred embodiment of the hybridization assay of the present invention for 0.5 μ l of a PCR reaction.

15 The black square symbol represents 25 cycles of PCR. The plus symbol represents 27 cycles of PCR. The asterisk symbol represents 30 cycles of PCR. The black triangle symbol represents a negative control with no PCR cycles.

20 Figure 4 is a schematic representation of a second preferred embodiment of the hybridization assay of the present invention for detection of DNA that has been amplified by PCR.

Detailed Description of the Invention

25 A non-radioactive hybridization assay and kit are provided for the detection of amplified nucleic acid sequences and target nucleic acid sequences specific for genetic disorders, microorganisms and viruses such as the DNA of Chlamydia, human papilloma virus 30 (HPV), and hepatitis B virus.

As shown schematically in Figure 1, a first preferred embodiment of the assay, for detection of target nucleic acid sequences, is performed generally as follows.

A sample such as blood or an exfoliated cervical cell specimen is collected and subjected to alkaline pH to denature and, if necessary, nick the nucleic acids in the sample. The treated, or hydrolyzed, 5 target nucleic acids are hybridized to a probe or group of probes diluted in a neutralizing buffer. Most preferably, the target nucleic acids are DNA and the probe is a complementary RNA sequence.

An anti-hybrid antibody, either polyclonal or 10 monoclonal, is immobilized on a solid phase such as a test tube or polystyrene bead. It will be understood by those skilled in the art that the immobilized antibody can be bound directly to the solid phase or indirectly by use of a primary binding 15 antibody or protein, such as streptavidin or protein G, that is bound to the solid phase and which subsequently binds the anti-hybrid antibody, a derivatized anti-hybrid antibody, a functional fragment of the anti hybrid antibody, or a 20 derivatized functional fragment of the anti-hybrid antibody. Any solid phase such as plastic or glass microparticles, beads, dip-sticks, test tubes or microtiter plates can be used.

The hybridized sample is placed in the antibody- 25 coated tube for a sufficient amount of time to allow binding or capture of the hybrid by the anti-hybrid antibody. An enzyme that digests single-stranded RNA or RNA-RNA hybrids, such as an RNAase is then added to the sample to eliminate any non-hybridized probe. 30 Most preferably, the RNAase and a hybrid detection means, described below are combined as a single reagent. Alternatively, non-hybridized probe can be removed by washing the sample.

Hybridization is then detected by conventional 35 means well known in the art such as with a direct labelled polyclonal or monoclonal antibody specific for the hybrid, a labelled antibody specific for an

unlabelled anti-hybrid antibody, or the RNA probe or probes can be directly labelled, or modified and detected with a labelled antibody specific for the modified probe. Most preferably, the label is an enzyme, a fluorescent molecule or a biotin-avidin conjugate and is non-radioactive. The label can then be detected by conventional means well known in the art such as a colorimeter, a luminometer or a fluorescence detector.

10 As shown schematically in Figure 4, a second preferred embodiment of the hybridization assay, for detection of amplified nucleic acid sequences, is performed generally as described above with the following modifications.

15 Primers for amplification of the nucleic acid sequences of interest contained in the sample are attached to a ligand, such as biotin. Preferably, for PCR amplification, 5'-biotinylated primers are synthesized or purchased from commercially available 20 sources such as National Biosciences Inc. (Plymouth, MN).

25 Prior to treatment with alkaline pH as described above, nucleic acid sequences in the sample are amplified, using the ligand-bound primers, in accordance with conventional amplification methods as described in more detail below. The resulting amplification products are then subjected to alkaline pH and are hybridized to a probe or group of probes as described above.

30 Instead of coating the solid phase with an anti-hybrid antibody as described above, the solid phase is coated with a ligand complementary to the ligand that is attached to the primer. For example, if the primer is biotinylated, then the solid phase is 35 coated with a complementary ligand such as streptavidin. Most preferably, streptavidin-coated microtiter plates are used. These plates may be

coated passively or purchased commercially from Xenopore (Saddle Brook, NJ) or prepared using the methods outlined below for immobilization of anti-hybrid antibody.

5 The non-radioactive hybridization assay and kit is described in more detail as follows.

Sample Collection and Hydrolysis

An exfoliated cell sample is collected with a chemically inert collection device such as a dacron 10 tipped swab as shown in Figure 1. The sample and collection device are stored in a transport medium that preserves nucleic acids and inhibits nucleases such as a chaotropic salt solution, a detergent solution such as sodium dodecyl sulfate (SDS), 15 preferably 0.5% SDS, or a chelating agent solution such as ethylenediaminetetraacetic acid (EDTA), preferably 100 mM, to prevent degradation prior to analysis. Most preferably, the sample and collection device are stored in the chaotropic salt solution 20 provided as the sample transport medium the ViraPap™ human papilloma virus test kit available from Digene Diagnostics, Inc. (Silver Spring, MD). Alternatively, the sample can be collected and stored in the base hydrolysis solution described below.

25 If the nucleic acids to be detected are present in blood, such as HBV DNA, a blood sample is collected with a syringe, and serum is separated by conventional means. Preferably, serum is incubated for approximately 20 minutes at approximately 65°C 30 with a protease, such as proteinase K, available from Sigma (St. Louis, MO), prior to base treatment as described below.

The sample is treated with a base, or hydrolyzed, to render the target nucleic acid 35 accessible to hybridization. Nucleic acids are denatured and, if necessary, nicked by incubating the sample and collection device, if present, in 0.1 to

2.0 M base at 20 to 100°C for 5 to 120 minutes. Preferably, treatment is achieved with 0.2 to 0.8 M NaOH, or a similar base such as KOH, at 60-70°C for 30 to 60 minutes. Most preferably, the sample and 5 swab are incubated in 0.415 M NaOH for 65°C for 45 minutes. Approximately one volume of sample is treated with one-half volume of base, also referred to herein as the hydrolysis reagent. The pH will be approximately 13. This basic pH will both nick and 10 denature a majority of the nucleic acid in the specimen. In addition, base treatment disrupts interactions between peptides and nucleic acids to improve accessibility of the target nucleic acid, degrade protein, and liquify mucous. Base treatment 15 of protein and mucous effectively homogenizes the specimen to ensure reproducibility of analysis results for a given sample. Base treatment also reduces the viscosity of the sample to increase kinetics, homogenize the sample, and reduce 20 background by destroying any existing DNA-RNA or RNA-RNA hybrids in the sample. It is believed that base treatment also inactivates enzymes such as RNAases present in the sample that could potentially degrade RNA probes used in the assay.

25 Amplification

The nucleic acid sequences to be detected in the sample can be amplified in accordance with methods well known to those skilled in the art, prior to hydrolysis. Amplification is especially useful when 30 the sample contains only trace amounts of the nucleic acid sequences to be detected. Figure 3 shows detection of amplified nucleic acid sequences, amplified by the polymerase chain reaction (PCR) using the first preferred embodiment of the 35 hybridization assay described herein.

For improved detection of amplified target nucleic acid sequences, a primer or primers, to which a

ligand is attached, are used in accordance with the second preferred embodiment of the hybridization assay. The ligand is attached to the primer by conventional methods well known to those skilled in the art such as those described below for immobilization of anti-hybrid antibody to a solid phase. Alternatively, a commercially available ligand-bound primer is purchased from a supplier such as National Biosciences Inc. (Plymouth, MN)

10 The primers are used as single primers or in pairs as primers to amplify the DNA or RNA to be detected in the sample. The primers are used in conjunction with any applicable amplification technology to amplify the nucleotide sequences located between the primers to detectable levels. Examples of applicable amplification systems that currently exist or are being developed include polymerase chain reaction (PCR), PCR *in situ*, ligase amplification reaction (LAR), ligase hybridization, Q8 bacteriophage replicase, transcription-based amplification system (TAS), genomic amplification with transcript sequencing (GAWTS) and nucleic acid sequence-based amplification (NASBA). General reviews of these methods have been prepared by Landegren, U., et al., 15 *Science* 242:229-237 (1988) and Lewis, R., *Genetic Engineering News* 10:1, 54-55 (1990).

20

25

PCR technology is described in *PCR Protocols A Guide to Methods and Applications* by Michael A. Innis, David H. Gelfand, John J. Sninsky and Thomas J. White, pp. 39-45 and 337-385 (Academic Press, Inc., Harcourt Brace Jovanovich, Publishers, 1990), the teachings of which are incorporated by reference herein. PCR technology is also described by Marx, J.L., *Science* 140:1408-1410 (1988) and in U.S. Patent Nos. 4,683,195 and 4,683,202, to Mullis, the teachings of which are also incorporated herein by reference.

PCR using one primer is described by Loh, E.Y., et al., *Science* 243:217 (1989), the teachings of which are incorporated herein by reference. This technique is often used with cDNA (DNA derived from messenger RNA by reverse transcriptase). There are also assymetric PCR systems and other methods that use one primer or vast excess of one primer. These methods generate mostly single-stranded DNA, suitable for direct sequencing. Single primers can also be used with random hexamers (a degenerate mixture of all or most of the possible DNA hexamers) so that at least one hexamer will act as a second primer by hybridizing somewhere along the sequence at a distance from the first primer.

PCR *in situ* is the use of PCR amplification on cells or tissue sections followed by detection using *in situ* hybridization. This technique is described by Haase, A.T., et al., "Amplification and detection of lentiviral DNA inside cells", *Proc. Natl. Acad. Sci. (USA)* 87:4971-4975 (July 1990).

Ligase amplification reaction is described by Wu, D.Y and Wallace, R.B, *Genomics* 4:560-569 (1989) and Barringer, K.J., et al., *Gene* 89:117-122 (1990), the teachings of which are incorporated herein by reference. Ligase hybridization is described by Landegren, U., et al., *Science* 241:1077-1080 (1988), the teachings of which are incorporated herein by reference.

The Q8 bacteriophage replicase system is described by Kramer, F.R. and Lizardi, P.M., "Replicatable RNA reporters", *Nature* 339:401-402 (1989); Lizardi, P.M., et al., "Exponential amplification of recombinant-RNA hybridization probes", *Bio/Technology* 6:1197-1202 (1988); Lomeli, H., et al., "Quantitative assays based on the use of replicatable hybridization probes", *Clin. Chem.* 35:1826-1831 (1989); and Chu, B.C.F., et al., *Nucl. Acids Res.* 14:5591-5603 (1986),

the teachings of which are incorporated herein by reference.

5 TAS is described by Kwoh, D.Y., et al., Proc. Natl. Acad. Sci. USA 86:1173-1177 (1989), the teachings of which are incorporated herein by reference.

10 GAWTS is described by Stoflet, E.S., et al., Science 239:491-494 (1988), the teachings of which are incorporated herein by reference.

15 NASBA is described by Compton, J., Nature 350:91-92 (1991), the teachings of which are incorporated herein by reference.

Hybridization

20 Non-radioactive RNA probes are synthesized or isolated in accordance with methods well known in the art as described by Maniatis, T., et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989). For example, HPV probes can be synthesized from linearized plasmid template using phage T7 RNA polymerase obtained from Bethesda Research Labs (Gaithersburg, MD).

25 In the preferred embodiment, the probes are HPV RNA, most preferably a mixture of HPV 6 and HPV 11, which are associated with benign lesions, or a mixture of HPV 16, HPV 18, HPV 31, HPV 33, and HPV 35, which are associated with an increased risk of cervical cancer. Probes are preferably single-stranded RNA of approximately 20-10,000 bases in 30 length. Mixtures of probes for use in screening assays include mixtures of HPV types 6, 11, 33, 42, 43, and 44 RNA probes; HPV types 16, 18, 31, 33, and 35; and HPV types 6, 11, 16, 18, 31, and 35 RNA. Probes are prepared by enzymatic or chemical in vitro 35 synthesis. Probes can also be prepared so that they are linked to detectable labels, such as an enzyme,

or to a hapten such as biotin that can then be detected with an anti-hapten antibody.

Preferably, the probe is diluted in a probe diluent that also acts as a neutralizing hybridization buffer. The diluent is used to dissolve and dilute the probe and also helps restore the sample to neutral pH, between approximately pH 6 and pH 9, to provide a more favorable environment for hybridization. Sufficient volume of probe diluent, 5 preferably one-half volume, is used to neutralize one and one-half volume of base-treated sample. Preferably, the probe diluent is a 2-[bis(2-Hydroxyethyl) amino] ethane sulfonic acid (BES, Sigma, St. Louis, MO)/sodium acetate buffer. Most 10 preferably, the probe diluent is a mixture of 2 M BES, 1 M sodium acetate, 0.05% of the antimicrobial agent NaN_3 , 5 mM of the metal chelating agent EDTA, 15 0.4% of the detergent TweenTM-20 and 20% of the hybridization accelerator dextran sulfate. The pH of 20 the probe diluent is between approximately 5 to 5.5. The concentration of each probe in the probe diluent is from 1 to 500 ng/ml. Preferably, the concentration of probe is 20 to 200 ng/ml. Most 25 preferably, the concentration of each probe is approximately 75 ng/ml.

After treatment with base, an aliquot of sample is removed from the sample tube or an aliquot of amplification product is removed from the vessel in which amplification was conducted and combined with 30 a sufficient amount of probe, dissolved in the above-described probe diluent, to allow hybridization. Preferably, 150 μl of base-treated sample are neutralized with 50 μl probe diluent. The probes and sample nucleic acids are incubated for approximately 35 5 to 120 minutes at 20 to 80°C to allow hybridization. Preferably, RNA probes and sample DNA are incubated for 30 to 60 minutes at 50 to 80°C.

Most preferably, the RNA probes and DNA in the sample are incubated for 60 minutes at 65°C.

Preparation of Anti-hybrid Antibodies for Capture

Any anti-hybrid antibodies may be used to capture 5 the hybrid onto the solid phase that are specific for a double-stranded RNA/DNA. In a preferred embodiment of the present assay, a polyclonal anti-RNA/DNA hybrid antibody is derived from goats immunized with an RNA/DNA hybrid. Hybrid-specific antibody is 10 purified from the goat serum by affinity purification against RNA/DNA hybrid immobilized on a solid support. Monoclonal antibody prepared using standard techniques can be used in place of the polyclonal antibodies.

15 The preferred antibody for capture of RNA/DNA hybrids is prepared by the method of Kitawaga, Y. and Stollar, B.D., *Mol. Immunology* 19:413-420 (1982) or according to the method set forth in U.S. Patent No. 4,732,847, issued March 22, 1988 to Stuart et al., 20 both of which are incorporated herein by reference.

It will be understood by those skilled in the art that either polyclonal or monoclonal anti-hybrid antibodies can be immobilized on the solid phase in the present assay as described below.

25 Immobilization of Anti-hybrid Antibody

The anti-hybrid antibody is immobilized onto a solid phase such as a test tube surface. It will be understood by those skilled in the art that a solid phase includes polystyrene, polyethylene, 30 polypropylene, polycarbonate or any solid plastic material in the shape of test tubes, beads, microparticles, dip-sticks or the like. A solid phase also includes glass beads, glass test tubes and any other appropriate shape made of glass. A 35 functionalized solid phase such as plastic or glass that has been modified so that the surface contains carboxyl, amino, hydrazide or aldehyde groups can

also be used. Immobilization of the antibody can be direct or indirect. Preferably, test tubes are directly coated with anti-hybrid antibody in accordance with methods known to those skilled in the art or briefly described below. The antibody can also be biotinylated and subsequently immobilized on streptavidin coated tubes, or modified by other means to covalently bind to the solid phase. Solubilized biotinylated antibody can be immobilized on the streptavidin coated tubes before capture of the hybridized samples as described below or in conjunction with the addition of the hybridized samples to simultaneously immobilize the biotinylated antibody and capture the hybrids.

Most preferably, the antibody is attached to the solid phase in accordance with the method of Fleminger, G., et al., *Appl. Biochem. Biotech.* 23:123-137 (1990), by oxidizing the carbohydrate portion of the antibody with periodate to yield reactive aldehyde groups. The aldehyde groups are then reacted with a hydrazide-modified solid phase such as MicroBind-HZTM microtiter plates available from Dynatech Laboratories (Chantilly, VA). Passive coating of the antibody according to the well known method of Esser, P., Nunc Bulletin No. 6 (Nov. 1988) (Nunc, Roskilde, Denmark) is also acceptable.

Alternatively, Vortex StarTM tubes (Vortex Laboratories Inc., Portland, ME) are coated with streptavidin by the method of Haun, M. and Wasi, S., *Anal. Biochem.* 191:337-342 (1990). After binding of streptavidin the biotinylated goat polyclonal antibody described above, or otherwise produced by methods known to those skilled in the art, is bound to the immobilized streptavidin. Following antibody binding, tubes can be post-coated with a detergent such as TweenTM-20 and sucrose to block unbound sites on the tube and stabilize the bound proteins as

described by Esser, P., Nunc Bulletin No. 8, pp. 1-5 (Dec. 1990) and Nunc Bulletin No. 9, pp. 1-4 (June 1991) (Nunc, Roskilde, Denmark) and Ansari, et al., *J. Immunol. Methods* 84:117-124 (1985). Preferably, 5 each tube is coated with between 10 ng and 100 µg biotinylated antibody. Most preferably each tube is coated with approximately 250 ng of biotinylated antibody.

As discussed above, the solid phase can be coated 10 with functional antibody fragments or derivatized functional fragments of the anti-hybrid antibody.

For capture of a nucleic acid sequence that has been amplified as described above, the solid phase is coated with ligand complementary to the ligand that 15 is bound to the amplification primer. For example, for capture of a sequence that has been amplified with an avidin-bound primer, the solid phase is coated with streptavidin as described above.

Capture

20 Hybridized samples are incubated in the anti-hybrid coated tubes for a sufficient amount of time to allow capture of the hybrids by the immobilized antibodies or complementary ligand. The hybrids are bound to the immobilized antibodies or 25 complementary ligand by incubation for 5 minutes to 24 hours at 15 to 65°C on a platform shaker with a shaking speed of 0 to 1500 rpm. Preferably, the incubation time is 30 to 120 minutes at 20 to 40°C, with shaking at 300 to 1200 rpm. Most preferably, 30 capture occurs with incubation at one hour at room temperature with vigorous shaking on a rotary platform shaker with a rotary shaking speed between approximately 300 and 1000 rpm. It will be understood by those skilled in the art that the 35 incubation time, temperature, and shaking can be varied to achieve alternative capture kinetics as desired.

Conjugation of Anti-hybrid Antibody

An antibody, specific for the RNA/DNA hybrid is conjugated to a label for detection of captured hybridized probe by well known conjugation methods.

5 Preferably, an antibody, such as the mouse monoclonal antibody deposited with the American Type Culture Collection as ATCC Accession number HB-8730, is conjugated to a detectable label such as alkaline phosphatase. It will be understood by those skilled
10 in the art that any detectable label such as an enzyme, a fluorescent molecule or a biotin-avidin conjugate can be used.

The antibody conjugate is produced by well known means such as direct reduction of the monoclonal
15 antibody with dithiothreitol, (DTT, Sigma Chemical Company, St. Louis, MO) to yield monovalent antibody fragments. The reduced antibody is then directly conjugated to maleimated alkaline phosphatase by the methods of Ishikawa et al., *J. Immunoassay* 4:209-237
20 (1983) and Means, G. and Feeney, R., *Bioconj. Chem.* 1: 2-12 (1990) and the resulting conjugate is purified by HPLC.

Alternatively, captured hybrid can be detected indirectly using an unlabelled anti-hybrid antibody
25 for which a labelled antibody is specific. For example, the anti-hybrid antibody can be a mouse immunoglobulin that is detected by a labelled goat anti-mouse antibody.

In addition, captured hybrid can be detected by conjugating the RNA probe used for hybridization to a label, such as an enzyme, or to a hapten, such as biotin that is then detected with a labelled anti-hapten antibody.

Excess Probe Digestion and Hybrid Detection

35 After capture, any excess sample is removed from the capture tube, a solution preferably containing both a single-stranded RNA digestion enzyme such as

RNAase at a concentration between 0.01 and 1 mg/ml and the above described conjugated anti-hybrid molecule is added to the tube, and the tube is incubated for approximately 5 minutes to 24 hours at 5 temperature between 4 and 45°C. The purpose of the RNA digestion enzyme is to degrade non-hybridized probe that may be bound to the tube. It is important to remove the excess probe because secondary structures in the nucleic acid can be recognized by 10 the detection means, resulting in elevated assay background. Preferably, the enzyme is added at a concentration between 0.05 and 0.5 mg/ml and is incubated for between 10 and 60 minutes. Most preferably, the enzyme is RNase A (Sigma, St. Louis, 15 MO) and is incubated with the captured DNA for approximately 30 minutes at a concentration of 200 µg/ml. RNase III (NCI, Frederick, MD) can also be used.

The RNase and conjugate are preferably diluted in 20 a conjugation buffer that promotes specific antibody-antigen interaction, blocks non-specific binding of conjugate to the capture tube and stabilizes conjugate for long-term storage. A preferred buffer contains 0.1 M Tris™-HCl, pH 7.5, 25 0.6 M NaCl to reduce cross reaction of antibody with other nucleic acid species, ZnCl₂ and MgCl₂ for stabilizing alkaline phosphatase, normal goat serum to block non-specific interaction of conjugate with the capture surface, 0.25% Tween™-20 to block 30 non-specific binding of conjugate, and sodium azide as a preservative. A preferred wash buffer contains 0.1 M Tris™-HCl, pH 7.5, 0.6 M NaCl, 0.25% Tween™-20, and sodium azide as a preservative.

Detection of captured hybrid is preferably 35 achieved by binding the above-described conjugated anti-hybrid molecule to the hybrid during this incubation. Tubes are then washed with the above-

described wash buffer to remove any excess conjugate. Preferably, five manual washes are performed using either an Eppendorf™ Repeat Pipettor with a 50 ml Combitip™ (Eppendorf, Hamburg, Germany), a Corning™ 5 repeat syringe (Corning, Corning, NY), a simple pump regulated by a variostat, or by gravity flow from a reservoir with attached tubing. Commercially available tube washing systems available from Source Scientific Systems (Garden Grove, CA) can also be 10 used.

As described above, captured hybrid can also be detected with a direct labelled RNA probe, such as an enzyme-conjugated hybridization probe, or a hapten-modified probe that is subsequently detected by a 15 labelled anti-hapten antibody.

Bound conjugate is subsequently detected by colorimetry or chemiluminescence as described by Coutlee, et al., *J. Clin. Microbiol.* 27:1002-1007 (1989). Preferably, bound alkaline phosphatase 20 conjugate is detected by chemiluminescence with a reagent such as a Lumi-Phos™ 530 reagent (Lumigen, Detroit, MI) using a detector such as an E/Lumina™ luminometer (Source Scientific Systems, Inc., Garden Grove, CA) or an Optocomp I™ Luminometer (MGM 25 Instruments, Hamden, CT).

Non-radioactive hybridization kit

The non-radioactive hybridization assay kit contains the necessary devices and reagents for performing the non-radioactive hybridization assay 30 described above including an inert sample collection device, such as a dacron swab for exfoliated cell sample collection; sample transport medium for stabilization of the sample during transport to the laboratory for analysis; a ligand-bound nucleic acid 35 primer, for amplification of nucleic acid sequences, if amplification is conducted; base, or hydrolysis reagent; one or more probes specific for the nucleic

acid to be detected; neutralizing probe diluent; anti-hybrid antibody- or complementary ligand-coated test tubes or microtiter wells; a nuclease such as RNAase, preferably contained in a solution also 5 containing a conjugated anti-hybrid antibody that can be detected by conventional means; and any necessary controls.

Preferably, for a hybridization kit in which amplification is not utilized, the sample transport 10 medium is the ViraPapTM Sample Transport Medium (STM) available from Digene Diagnostics, Inc. (Silver Spring, MD); the base is 0.415 M NaOH; the neutralizing probe diluent is a BES/sodium acetate buffer; the test tubes are Vortex StarTM tubes coated 15 with a polyclonal anti-hybrid antibody; and the conjugated anti-hybrid antibody is a mouse monoclonal antibody conjugated to alkaline phosphatase. Preferably, the kit also contains a substrate for the 20 chemiluminescent detection of alkaline phosphatase, such as a Lumi-PhosTM 530 reagent (Lumigen, Detroit, MI).

The kit should contain a negative control and a positive control for each probe. Preferably, the negative control is sonicated herring sperm DNA (100 25 pg/ml) dissolved in sample transport medium. The positive control preferably contains herring sperm DNA (100 pg/ml) and probe target nucleic acid.

In general, the assay can be used to detect as little as 1.0 pg to 10 ng DNA per ml of specimen with 30 a typical specimen volume of 0.1 ml.

The hybridization kit for detection of amplified nucleic acid sequences preferably contains a sample transport medium such as the ViraPapTM Sample Transport Medium (STM) available from Digene 35 Diagnostics, Inc. (Silver Spring, MD) with sodium azide; the base is 1.25N NaOH; the neutralizing probe diluent is a BES/sodium acetate buffer with sodium

azide; the microtiter wells are streptavidin-coated plates; and the conjugated anti-hybrid antibody is a mouse monoclonal antibody conjugated to alkaline phosphatase. Preferably, the kit also contains a 5 substrate for the chemiluminescent detection of alkaline phosphatase, such as a Lumi-PhosTM 530 reagent (Lumigen, Detroit, MI).

The kit should contain a negative control and a positive control for each probe. Preferably, the 10 negative control is mock PCR reaction buffer. The positive control preferably contains 150 pM 5'-biotinylated PCR product in a mock PCR reaction buffer.

In general, the assay can be used to detect as 15 little as 1.0 pg to 10 ng DNA per ml of specimen with a typical specimen volume of 0.1 ml. The following non-limiting examples illustrate use of the present assay and kit.

Example 1: Detection of HPV in Clinical Human 20 Cervical Specimens.

Cervical samples were collected with a dacron swab and stored in 1 ml ViraPapTM prior to analysis. All of the patients had a history of HPV infection. One-half ml (0.5 ml) of a 1.25 M NaOH 25 hydrolysis reagent was added to the 1 ml specimen for a final concentration of 0.415 N NaOH. The sample and swab were subjected to hydrolysis for 40 minutes at 65°C.

After hydrolysis, a 150 μ l aliquot was removed 30 from the sample tube and added to 50 μ l of a probe diluent containing Probe A, B or C. Probe A contained RNA probes to HPV types 6, 11, 42, 43, and 44. Probe B contained RNA probes to HPV types 16, 18, 31, 33, 35, 45, 51, 52, and 56. Probe C 35 contained RNA probes to HPV types 6, 11, 16, 18, 31, 33, and 35. Probes were synthesized from

linearized plasmid template using phage T7 RNA polymerase. The probe diluent was a BES/sodium acetate buffer including 2 M BES, 1 M sodium acetate, 0.05% NaN₃, 5 mM EDTA, 0.4% Tween-20 and 5 20% dextran sulfate. The pH of the probe diluent was between approximately 5 and 5.5. The probe mixture was hybridized at 65°C for one hour.

Hybridized nucleic acids were captured onto an anti-hybrid coated Vortex Star™ test tubes by 10 shaking at 300-1000 rpm at room temperature for one hour. A solution containing RNAase at 0.2 mg/ml was added to digest any non-hybridized probe, and monoclonal anti-hybrid antibody conjugated to alkaline phosphatase was added to the captured 15 hybrid. The excess RNase and conjugate was discarded, and tubes were washed five times with a buffer. Tubes were loaded into an E/Lumina™ luminometer for addition of LumiPhos™ 530 and measurement of chemiluminescence. The results are 20 shown in Table I. The non-radioactive hybridization assay results were correlated with results using the ViraType™ HPV DNA test (Digene Diagnostics, Silver Spring, MD) performed as described below. Three times background was used 25 as the positive/negative cutoff in analysis of the data. The results with Probe C (6, 11, 16, 18, 31, 33, 35) correlated well with the ViraType™ results. One additional positive was detected with Probe C (patient 15) probably due to slightly better 30 sensitivity of the non-radioactive hybridization assay. Additional positive patients (2, 9, 12 and 22) were identified with Probe A and Probe B, presumably due to the use of probes for additional HPV types.

35 The ViraType™ HPV DNA detection method is performed as follows. Exfoliated cervical cells are collected with a swab or scraper, or biopsies

are obtained. The specimen is disrupted to release viral DNA, and the DNA is denatured and bound to a solid support by filtration through a set of three replicate nylon membranes having a high affinity for nucleic acids. HPV target DNA bound to the three replicate membranes is then hybridized to three ^{32}P -radiolabelled RNA probe groups specific for HPV types 6/11, 16/18, or 31/33/35. Following hybridization, each of the three nylon membranes are treated with ribonuclease and washed to remove unhybridized probe. The presence of bound ^{32}P -labelled RNA probe is detected by autoradiography of the three nylon membranes.

| patient # | probe A | probe B | probe C | Viratype | Comments |
|-----------|---------|---------|---------|------------------|---------------------------------|
| 1 | +++ | +++ | +++ | +++ 16/18 | |
| 2 | +++ | +++ | - | - | |
| 3 | - | - | - | - | |
| 4 | - | - | - | - | |
| 5 | - | - | - | - | |
| 6 | - | - | - | - | |
| 7 | - | - | - | + 6/11, 16/18 | |
| 8 | - | - | - | - | suggests novel type, Probe A |
| 9 | - | - | - | + 16/18 | |
| 10 | - | - | - | - | |
| 11 | - | - | - | - | |
| 12 | - | - | - | - | |
| 13 | - | - | +++ | - | |
| 14 | - | - | - | - | |
| 15 | - | - | - | - | |
| 16 | - | - | - | ++ 16/18 | |
| 17 | - | - | - | ++ 16/18 | |
| 18 | - | - | +++ | ++ 16/18 | |
| 19 | - | - | - | - | |
| 20 | - | - | - | ++ 16/18 | |
| 21 | - | - | - | ++ 16/18 | |
| 22 | - | - | - | +/- 16/18 | |
| 23 | - | - | +++ | +/- 16/18 | suggests novel type, Probe A |
| 24 | - | - | - | - | |
| 25 | - | - | - | ++++ 16/18 | |
| 26 | - | - | - | - | |
| 27 | - | - | - | +++ 16/18 | |
| 28 | - | - | - | - | |
| 29 | - | - | - | ++ 30's | |

Example 2: Assay of Known Positive Samples.

Samples known to be positive for HPV 16 infection based on results using the ViraType™ HPV detection kit (Digene Diagnostics, Silver Spring, MD) were analyzed using the non-radioactive hybridization assay as described in Example 1 with an HPV 16-specific probe. The results indicated good correlation between the quantitative chemiluminescent assay and the semi-quantitative dot blot as shown in Table II.

Table II
Detection of Clinical Samples Using Antibody Tube Assay¹:
correlation of Viratype Dot Blot signal With Chemiluminescent Output

| <u>Clinical Samples in order of Viratype Intensity</u> | <u>Chemiluminescent Output</u> | <u>Viratype Result</u> |
|--|------------------------------------|----------------------------|
| H215 | 453, 986 | + |
| H216 | 506, 927 | + |
| Y26 | 15, 268 | + |
| H209 | 13, 913 | + |
| Y25 | 17, 745 | + |
| H409 | 12, 168 | + |
| H357 | 5, 451 | + |
| Y181 | 6, 605 | + |
| H259 | 3, 025 | + |
| Y205 | 3, 219 | + |
| Y97 | 2, 349 | + |
| H423 | 1, 463 | + |
| Y44 | 2, 048 | + |
| H347 | 1, 107 | + |
| Y209 | 1, 237 | - |
| H33 | 706 | - |
| Y110 | 628 | - |
| Y109 | 650 | - |
| H401 | 508 | - |
| Y98 | 785 | - |
| H297 | 487 | - |

Pool of 20 Viratype Negative Samples

| 100 μ l Assayed (no HPV added) | 10 pg HPV 16 DNA Added to 100 μ l of negative pool |
|---------------------------------------|---|
| 458 | 1,386 |
| 429 | 1,366 |
| 447 | 1,496 |

¹Tubes used in this assay were streptavidin coated tubes prebound with biotinylated polyclonal antibody.

Example 3:
Specimens.**Effect of Blood in**

Interference by blood in specimens is one of the limitations of the HPV assays presently available. Blood does not interfere in the present non-radioactive hybridization assay.

Bloody cervical specimens were spiked with plasmid DNA and screened with the non-radioactive hybridization assay described in Example 1. The results are shown in Table III. Samples ranged from light to heavy blood contamination. Even in the bloodiest specimen, there was no interference in detection of target DNA, even though this sample contained brown particulate matter after hybridization.

Table III
Effect of Blood in Specimens

Relative Light Units

| <u>Sample</u> | <u>10 pg DNA</u> | <u>No DNA</u> | <u>Sample Description</u> |
|---------------|----------------------|---------------|---------------------------------|
| A | 1014 | 40 | clean system |
| B | 1146 | 43 | clinical - clear |
| C | 1162 | 37 | clinical - pale yellow |
| D | 1000 | 37 | clinical - brownish yellow |
| E | 1221 | 40 | clinical - translucent brown |
| F | 1179 | 37 | clinical - dark rust |

¹Average of duplicates.

Example 4: Evaluation of Hybrid Capture HPV DNA Assay on a Panel of Clinically Characterized Specimens.

One-hundred and ninety-nine women with equivocal Pap smears were enrolled in a study. 5 Each had a specimen of exfoliated cervical cells sampled by lavage and subjected to HPV DNA testing. The Pap smears of each woman were also re-read by a panel of expert pathologists who arrived at a 10 consensus diagnosis. The specimens for HPV testing were placed in standard Sample Transport Medium manufactured by Digene Diagnostics, Inc. as part of its ViraPapTM test kit. Each specimen was tested 15 with both the non-radioactive hybridization assay as set forth below and a Southern blot method well described in the literature and in particular by Lorincz A.T. et al., J. Virol. 58:225 (1986).

Samples were tested by the non-radioactive hybridization assay by first pipetting 500 μ l 20 hydrolysis reagent into control and sample tubes. The tubes were capped and vortexed and incubated in a 65°C waterbath for 45 \pm 5 minutes. Appropriate mixtures of probes for oncogenic and non-oncogenic HPV were prepared as probes A and B respectively. 25 A 50 μ l aliquot of probe A, containing probes for HPV types HPV 6, HPV 11, HPV 16, HPV 18, HPV 31, HPV 33, HPV 35, HPV 42, HPV 43, HPV 44, HPV 45, HPV 51, HPV 52, and HPV 56, was pipetted into hybridization tubes and 150 μ l of denatured sample 30 was added. A 50 μ l aliquot of probe B containing probes for HPV types HPV 16, HPV 18, HPV 31, HPV 33, HPV 35, HPV 45, HPV 51, HPV 52, and HPV 56 was pipetted into a second set of hybridization tubes and 150 μ l of denatured sample was added. Tubes 35 were capped, vortexed, and incubated in a 65 \pm 2°C waterbath for 60 \pm 5 minutes. The contents from each tube were transferred into corresponding

capture tubes which had been coated with an anti-hybrid antibody and covered with Parafilm™. Tubes were shaken on a rotary shaker set at 1000 rpm at room temperature for 60 ± 5 minutes. Tubes were 5 decanted and blotted. A 250 µl aliquot of detection reagent containing an alkaline phosphatase-conjugated anti-hybrid monoclonal antibody and RNAase A was pipetted into each tube, shaken vigorously, and incubated at room 10 temperature for 30 ± 3 minutes. Tubes were decanted, washed five times, and drained. A 250 µl aliquot of a second detection reagent containing a chemiluminescent alkaline phosphatase substrate was pipetted into the tubes and incubated at room 15 temperature for 30 ± 3 minutes. Tubes were dried and read on a luminometer.

The data in Tables IV-VII show the performance of the non-radioactive hybridization assay versus clinical diagnoses (Tables IV-VI) and versus the 20 reference standard Southern blot test (Tables VII and VIII). In Table IV, the numbers in parenthesis are the numerical values whereas the numbers not in parenthesis are percent values. In Tables V and VII, the non-radioactive hybridization assay 25 contained RNA probes for the following HPV types: HPV 6, HPV 11, HPV 16, HPV 18, HPV 31, HPV 33, HPV 35, HPV 42, HPV 43, HPV 44, HPV 45, HPV 51, HPV 52, and HPV 56. In Tables VI and VIII, the non- 30 radioactive hybridization assay contained RNA probes for the following high risk HPV types: HPV 16, HPV 18, HPV 31, HPV 33, HPV 35, HPV 45, HPV 51, HPV 52, and HPV 56.

The comparisons demonstrate that the non-radioactive hybridization assay for HPV DNA 35 correlates well with the clinical diagnosis, and the values observed are similar to those reported in the literature using research methods. All

these values are consistent with an accurate and useful HPV DNA diagnostic test. The correlation of the non-radioactive hybridization assay for HPV DNA to Southern blot shown in Tables VII and VIII also 5 demonstrate a high level of accuracy for HPV DNA detection, especially when restricted to high risk HPV types.

Table IV

**Prevalence of High Risk and Low risk
Human Papillomavirus Sets in 199 Women
with Atypical Pap Smears Reread by a
Panel of Pathologists.***

| HPV DNA Result by Hybrid Capture | Diagnostic Category | | | HPV DNA Positive Total |
|--|---------------------|-----------|---------|---------------------------|
| | Normal | Equivocal | SIL+ | |
| Negative | 74 (89) | 42 (11) | 15 (8) | 54 (108) |
| Positive | 26 (32) | 58 (15) | 85 (44) | 46 (91) |
| High Risk | 17 (20) | 38 (10) | 77 (40) | 35 (70) |
| Low Risk | 10 (12) | 19 (5) | 8 (4) | 11 (21) |
| Total | (121) | (26) | (52) | (199) |

* Original diagnosis of all Pap smears was equivocal. Reclassification as shown in the table was the result of reread by 3 pathologists.
+ only 2 of 52 (4%) of SILs were high grade squamous intraepithelial lesions (HGSIL).

Table V

Contingency Table of HPV Positive Versus SIL Using Hybrid Capture*

| SIL (clinical diagnosis) | | Sens = 65 | |
|--------------------------|---|-----------|-----|
| | | + | - |
| Hybrid Capture | + | 44 | 32 |
| | - | 8 | 97 |
| | | 52 | 121 |
| | | 173 | |

* Equivocals excluded.

Table VI

Contingency Table of High Risk HPV Positive Versus SIL Using Hybrid Capture*

| SIL (clinical diagnosis) | | Sens = 77 | |
|--------------------------|---|-----------|-----|
| | | + | - |
| Hybrid Capture | + | 40 | 20 |
| | - | 12 | 101 |
| | | 52 | 121 |
| | | 173 | |

* Equivocals excluded.

Table VII

**Evaluation of Hybrid Capture
versus Southern Using the 199 Specimens
with Original Atypical Pap Smears
(the Schiffman Atypia Study)**

| Southern Any HPV | | + | - | |
|---------------------|-----|----|-----|----------------|
| Hybrid Capture | HPV | 75 | 16 | 91 |
| | | 14 | 94 | 108 |
| | | 89 | 110 | 199 |
| | | | | Sens = 81% |
| | | | | Spec = 85% |
| | | | | Accuracy = 85% |

Table VIII

| Southern High Risk HPVs | | + | - | |
|-------------------------------|-----|----|-----|----------------|
| Hybrid Capture | HPV | 50 | 8 | 58 |
| | | 0 | 94 | 94 |
| | | 50 | 102 | 152 |
| | | | | Sens = 100% |
| | | | | Spec = 92% |
| | | | | Accuracy = 95% |

**Example 5: Evaluation of the Hybrid Capture HBV
DNA Assay in Specimens of Human Serum.**

The non-radioactive hybridization assay was used to quantitate HBV DNA. Dose-response experiments were performed in clean model systems and also in human serum. The results of one such experiment are shown in Figure 2. In this experiment various amounts of HBV target DNA were diluted into a negative specimen of human serum and then assayed by the method set forth below.

HBV DNA in serum samples was quantitated by the non-radioactive hybridization assay by pipetting 50 μ l control or sample serum into test tubes. A 25 μ l aliquot of ViraPapTM sample transport medium (Digene Diagnostics, Inc., Silver Spring, MD) was pipetted into each tube. A 25 μ l aliquot of protease was pipetted into each tube, and the tubes vortexed. Tubes were incubated in a 65 \pm 2°C water bath for 20 \pm 5 minutes. A 50 μ l aliquot of a hydrolyzing reagent was pipetted into each tube, and tubes were shaken to mix. A 50 μ l aliquot of HBV probe was pipetted into each tube. Tubes were capped and vortexed, and incubated at 65°C for 60 \pm 5 minutes. The contents of each tube were transferred to a capture tube coated with anti-hybrid antibody. The capture tubes were covered with ParafilmTM and shaken on a rotary shaker for 60 minutes. Tubes were decanted and blotted. A 250 μ l aliquot of detection reagent containing RNAase A and an alkaline phosphatase-conjugated monoclonal antibody specific for the RNA/DNA hybrid was pipetted into each tube, tubes were shaken vigorously, incubated at room temperature for 30 \pm 3 minutes, decanted, washed five times and drained. A 250 μ l aliquot of a second detection reagent containing a chemiluminescent alkaline phosphate substrate was pipetted into each tube and incubated

at room temperature for 30 ± 3 minutes. Tubes were dried and read on a luminometer.

These data, set forth in Figure 2, show that the relationship between relative light units (RLUs) and picograms of DNA per 50 μ l of assay volume is approximately linear between 0.5 pg and 500 pg.

In another experiment 84 specimens of human serum from different individuals were tested with the non-radioactive hybridization assay and with another well characterized dot blot test for HBV DNA known as the HepProbe™ test, commercially available from Digene Diagnostics, Inc. (Silver Spring, MD). The results in Table IX demonstrate that the non-radioactive hybridization assay data were essentially equivalent, and slightly more sensitive, than the results obtained using the ^{32}P -labelled RNA probe based dot blot system. Overall these results show that the non-radioactive hybridization assay for HBV DNA is an accurate, fast, and quantitative non-radioactive test for HBV DNA in human serum.

Table IX

Comparison of Hybrid Capture
HBV DNA Test to HepProbe™

| HepProbe™ | | |
|-----------|---|----|
| HBV | + | - |
| Hybrid | + | 39 |
| Capture | - | 43 |

Sensitivity 100%
 Specificity 96% Accuracy = 98%

Example 6: Evaluation of Hybrid Capture for the Detection of *Chlamydia trachomatis* in Human Clinical Specimens.

For this study Dr. Julius Schachter of the 5 *Chlamydia* Laboratory, University of California, San Francisco, provided 54 cervical specimens which had been examined for *chlamydia* by direct culture. These specimens were not optimal for the non-radioactive hybridization assay described herein 10 because they were not collected in the preferred sample transport medium. The specimens had been stored for several months prior to assay, and less than the preferred specimen volume of 100 μ l was available in most cases. A preliminary analysis 15 was performed with the non-radioactive hybridization assay as described in Example 4, except that the probe diluent contained a single probe specific for *Chlamydia*. The probe was the full length cryptic plasmid transcribed into RNA. 20 Table X shows the results. The sensitivity of the DNA test was 79% and the specificity was 97%. The overall accuracy was 89% which is within an acceptable range.

Table X

**Preliminary Results
of Non-Radioactive Hybridization Assay *Chlamydia*
vs. Schachter *Chlamydia* Culture**

| | Culture | | | |
|----------------|---------|----|----|----|
| | + | - | | |
| Hybrid Capture | + | 19 | 1 | 20 |
| | - | 5 | 29 | 34 |
| | | 24 | 30 | 54 |

Sens = 79%

Spec = 97%

Modifications and variations of the non-radioactive hybridization assay and kit will be obvious to those skilled in the art from the foregoing detailed description of the invention. Such modifications and variations are intended to come within the scope of the appended claims.

5

We claim:

1. A non-radioactive hybridization assay for the detection of a target nucleic acid sequence in a biological sample the improvement comprising the steps

5 of:

- a) treating the sample with a base;
- b) hybridizing a nucleic acid sequence in the treated sample to a complementary nucleic acid probe to form a double-stranded hybrid;
- 10 c) capturing the hybrid onto a solid phase;
- d) eliminating any non-hybridized probe; and
- e) detecting the bound hybrid.

15 2. The assay of claim 1 wherein an anti-hybrid antibody or anti-hybrid fragment has been immobilized to the solid phase.

20 3. The assay of claim 1 comprising the additional step of amplifying the target nucleic acid sequence in the sample using a primer to which a first ligand has been attached before the base treatment step and wherein a second ligand complementary to the first ligand has been immobilized to the solid phase.

25 4. The assay of claim 3 wherein the target nucleic acid sequence is amplified by the polymerase chain reaction.

5. The assay of claim 1 wherein the non-hybridized probe is eliminated by digestion with RNAase.

26 6. The assay of claim 1 wherein the target nucleic acid sequence is DNA and the probe is an RNA sequence complementary to the target DNA.

30 7. The assay of claim 1 wherein the target nucleic acid is DNA selected from the group consisting of human papillomavirus DNA, hepatitis B DNA, and Chlamydia DNA.

8. The assay of claim 1 wherein the concentration of probe is between 1 and 500 ng/ml and the base is sodium hydroxide in a concentration of between 0.1 and 2.0 M, incubated with the sample at a 5 temperature between 20 and 100°C for a period of between 5 and 120 minutes.

9. The assay of claim 3 wherein the RNAase is added to the sample in a concentration between 0.01 and 1 mg/ml and incubated with the sample at a 10 temperature between 4 and 45°C for a period of between 5 minutes and 24 hours.

10. The assay of claim 1 further comprising diluting the probe in a buffer that restores the sample to a neutral pH wherein the buffer comprises 2-[bis(2-Hydroxyethyl) amino] ethane sulfonic acid and 15 sodium acetate.

11. A kit for the detection of a target nucleic acid sequence for diagnosing genetic defects, microbial or viral infections in a biological sample 20 comprising:

- a) a sample transport medium for stabilization of the biological sample;
- b) a base for treating the sample by nicking and degrading the target nucleic acid sequence 25 therein;
- c) a probe complementary to the treated target nucleic acid sequence for formation of a double-stranded nucleic acid hybrid;
- d) a neutralizing probe diluent for diluting the probe and neutralizing the treated target nucleic acid sequence;
- e) a solid phase coated with a coating to which a hybrid formed by hybridization of the probe and the target nucleic acid sequence, will 30 bind;
- f) means for eliminating any non-hybridized probe; and,

g) means for detecting the hybrid formed by hybridization of the probe and the target nucleic acid sequence.

12. The kit of claim 11 wherein the solid phase 5 is coated with an anti-hybrid antibody or an anti-hybrid antibody fragment, wherein the antibody is specific for a hybrid formed by hybridization of the probe and the target nucleic acid sequence.

10 13. The kit of claim 11 further comprising a primer to which a first ligand has been attached, for amplification of the target nucleic acid sequence and wherein the solid phase is coated with a second ligand, complementary to the first ligand, to which the first ligand will bind.

15 14. The kit of claim 11 wherein the means for eliminating the non-hybridized probe and the detecting means are combined in a single reagent.

15 15. The kit of claim 11 wherein the means for eliminating the non-hybridized probe is RNAase.


20 16. The kit of claim 11 wherein the target nucleic acid is DNA selected from the group consisting of human papillomavirus DNA, hepatitis B virus DNA and Chlamydia DNA.

25 17. The kit of claim 11 wherein the base is sodium hydroxide in a concentration of between 0.1 and 2 M.

30 18. A buffer for use in a hybridization assay comprising 2-[bis(2-Hydroxyethyl) amino] ethane sulfonic acid and sodium acetate wherein the pH of the buffer is between approximately 5 and 5.5.

19. The buffer of claim 18 further comprising an antimicrobial agent, a metal chelating agent, a detergent, and a hybridization accelerator.

35 20. The buffer of claim 19 further comprising a probe in a concentration between 1 and 500 ng/ml for hybridization to a target nucleic acid.






FIG. 2





FIG. 3



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 92/09604

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 C12Q1/68; C12Q1/70

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

| Classification System | Classification Symbols |
|-----------------------|------------------------|
| Int.Cl. 5 | C12Q |

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

| Category ¹⁰ | Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹² | Relevant to Claims No ¹³ |
|------------------------|---|-------------------------------------|
| X | WO,A,8 900 577 (IMPERIAL CANCER RESEARCH TECHNOLOGY) 26 January 1989 see claims | 1,11,14 |
| Y | EP,A,0 146 039 (MILES LABORATORIES) 26 June 1985 cited in the application see claims | 2-6,12, 13,15 |
| Y | JOURNAL OF IMMUNOLOGICAL METHODS. vol. 89, 1986, NEW YORK US pages 123 - 130 S. J. BOGUSLAWSKI ET AL. 'Characterization of monoclonal Ab to DNA*RNA and its application to immunodetection of hybrids' cited in the application see the whole document | 2,6,12 |
| | | -/- |

* Special categories of cited documents:¹⁰

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

IV. CERTIFICATION

| | |
|--|---|
| Date of Actual Completion of the International Search 18 MARCH 1993 | Date of Mailing of this International Search Report 26.03.93 |
| International Searching Authority EUROPEAN PATENT OFFICE | Signature of Authorized Officer MOLINA GALAN E. |

| III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET) | | |
|--|---|-----------------------|
| Category | Citation of Document, with indication, where appropriate, of the relevant passages | Relevant to Claim No. |
| Y | NUCLEIC ACIDS RESEARCH SYMPOSIUM SERIES no. 20, 1988, ARLINGTON, VIRGINIA US pages 91 - 92 A. YAMANE ET AL. 'Rapid detection of specific gene sequences' see the whole document | 3,4,13 |
| Y | EP,A,0 293 266 (CLAYTON FOUNDATION FOR RESEARCH) 30 November 1988 see page 4, line 18 - line 27; figure 11 | 5,15 |
| A | EP,A,0 209 702 (MILES LABORATORIES) 28 January 1987 | |

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9209604
SA 67125

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 18/03/93

| Patent document cited in search report | Publication date | Patent family member(s) | | Publication date |
|---|---------------------|----------------------------|----------|---------------------|
| WO-A-8900577 | 26-01-89 | EP-A- | 0377573 | 18-07-90 |
| | | JP-T- | 3503476 | 08-08-91 |
| EP-A-0146039 | 26-06-85 | AU-B- | 578436 | 27-10-88 |
| | | AU-A- | 3656084 | 20-06-85 |
| | | AU-B- | 578641 | 03-11-88 |
| | | AU-A- | 3656184 | 20-06-85 |
| | | AU-B- | 579335 | 24-11-88 |
| | | AU-A- | 3656284 | 20-06-85 |
| | | AU-B- | 580745 | 02-02-89 |
| | | AU-A- | 3656384 | 20-06-85 |
| | | CA-A- | 1250230 | 21-02-89 |
| | | CA-A- | 1239580 | 26-07-88 |
| | | CA-A- | 1250232 | 21-02-89 |
| | | CA-A- | 1238575 | 28-06-88 |
| | | EP-A- | 0144913 | 19-06-85 |
| | | EP-A- | 0144914 | 19-06-85 |
| | | EP-A, B | 0146815 | 03-07-85 |
| | | JP-A- | 60151559 | 09-08-85 |
| | | JP-A- | 60201256 | 11-10-85 |
| | | JP-A- | 60201257 | 11-10-85 |
| | | JP-A- | 60179657 | 13-09-85 |
| | | US-A- | 4563417 | 07-01-86 |
| EP-A-0293266 | 30-11-88 | AU-A- | 1983188 | 21-12-88 |
| | | AU-A- | 2038292 | 24-09-92 |
| | | EP-A, B | 0364490 | 25-04-90 |
| | | JP-T- | 4500751 | 13-02-92 |
| | | WO-A- | 8809387 | 01-12-88 |
| EP-A-0209702 | 28-01-87 | AU-B- | 558846 | 12-02-87 |
| | | JP-A- | 61293400 | 24-12-86 |